Home » Regions » Asia » Hepalink to acquire Cytovance

Hepalink to acquire Cytovance

Wednesday, August 26, 2015

Hepalink USA, a China-based global supplier of heparin sodium API, has entered into a definitive agreement to acquire Cytovance Biologics, a biopharmaceutical contract development manufacturing (CDMO) company, for $205.68 million in cash plus certain contingent payments.

The addition of Cytovance Biologics to Hepalink USA and its parent company Shenzhen Hepalink Pharmaceutical adds a biologics CDMO to its current U.S. portfolio, which also includes Wisconsin-based Scientific Protein Laboratories.

The transaction is expected to close in October following regulatory approval, at which point Cytovance Biologics will become a fully consolidated subsidiary of Hepalink USA. Cytovance management will remain in place, as will its 178 employees in the U.S.

Looking for more news, check out the new FREE CenterWatch Weekly!

The new FREE CenterWatch Weekly is your source of critical news, emerging trends, and business issues around everything in the rapidly changing clinical research marketplace. Check out our new CWWeekly page! Sign up today for your free email newsletter, update your bookmarks and check us out regularly! We look forward to bringing you the best news and information about clinical research in 2018!